1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

Azalea Vision Formed To Develop Artificial Iris

 
• By Reed Miller

Researchers have created the "smart contact lens" to dynamically improve the vision of people with various optical defects.

perfect blue eye macro in a sterile environment and perfect vision in resolution 6k, concept, the vision of the future and healthy life concept. view precise and straight to the target.
• Source: shutterstock.com

Azalea Vision is testing a novel artificial iris embedded in a smart contact lens that could eventually be used to improve visual acuity in people with iris deficiencies.

The company is a new spin-off of Ghent University and Imec, a nanoelectronics and digital technology research hub based in Leuven, Belgium, that works with affiliated research groups around the world

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

No Knife, No Burn, Just Bubbles: HistoSonics Hits 90% Tumor Control In #HOPE4Liver Trial, Eyes IPO Timing

 
• By Marion Webb

HistoSonics, which developed a noninvasive technology to destroy tumor cells, reports 90% local tumor control at 12-month follow-up in the #HOPE4Liver Trial. The Edison System, cleared by the US FDA in late 2023, is also being evaluated for kidney and pancreatic tumors. CEO Mike Blue said the medtech is financially secure but watching public markets as it considers an IPO.

Medtronic Presents Data To Boost Hugo’s Odds Of Getting FDA Nod

 
• By Brian Bossetta

Medtronic says results from a recent study on the Hugo robotic-assisted surgery system substantiate its safety and effectiveness for various urological procedures. The company also announced it has submitted the system to the FDA for approval for a urological indication.

First Liver Cancer Surveillance Test In Five Years Receives FDA Breakthrough Status

 
• By Natasha Barrow

Cambridge-based startup Mursla Bio's liquid biopsy test EvoLiver uses extracellular vesicles to detect hepatocellular carcinoma (HCC) in high-risk cirrhotic patients. Medtech Insight sat down with with Mursla Bio CEO Pierre Arsène.